www.alk.net
  • Your allergy
    • What is allergy
      • House dust mite allergy
      • Pollen allergy
      • Living with allergy
      • Socio-economic impact
    • What is allergic asthma
    • How is allergy diagnosed
    • Treating allergy
  • Our solutions
    • Consumer healthcare
    • Diagnostics
    • Allergy vaccines
      • Production
    • Emergency medicine
  • Our science
    • Allergy immunotherapy
    • Healthcare professionals
      • Reweal
      • Webinars
    • Pipeline
    • Clinical trials
    • Clinical data sharing
  • Our company
    • Newsroom
      • Stories
    • Privacy
    • Global presence
    • Organisation
    • History
    • Owners
  • Sustainability
  • Investors
    • Overview
    • Financial reporting
      • Risk management
      • Reporting standards
      • Auditors
    • Governance
      • IR policy
      • Board of Management
      • Board of Directors
      • Annual general meeting
      • Annual general meeting (DK)
    • News & Events
      • Company Releases
      • Company releases (DK)
      • Webcasts & presentations
      • Investor calendar
    • The Share
      • Dividend history
      • Analyst coverage
      • Analyst estimates
      • Shareholder information
      • Authorizations
      • ADR Programme
    • Contact IR
  • Careers
    • Working at ALK
    • Vacant positions
    • Cultural Beliefs
  • Select country
Search

Investors

The Share

See all

 


Company releases

See all

  • Post date: 12/01/21
    The Lancet Regional Health – Europe publishes ‘real-world evidence’ from ALK-sponsored study confirming long-term benefits of allergy immunotherapy in allergic rhinitis and asthma
    Read more
  • Post date: 11/11/21
    Nine-month interim report (Q3) 2021
    Read more
  • Post date: 11/05/21
    Release date of nine-month interim report (Q3) 2021 for ALK and audio cast
    Read more
  • Post date: 08/11/21
    Six-month interim report (Q2) 2021
    Read more
  • Post date: 08/09/21
    ALK upgrades its full-year financial outlook
    Read more
  • Post date: 08/05/21
    Change to ALK’s Board of Directors
    Read more

Featured Events
Nov 11, 2021
Nine-month interim report (Q3) 2021
Listen to audiocast
Nine-month interim report (Q3) 2021
View presentation here

Please call in before 1.25pm (CET). Danish participants should call in on tel. +45 3544 5577 and international participants should call in on tel. +44 333 300 0804 or +1 631 913 1422. Please use the following participant pin code: 25705608#

Please do not use Internet Explorer to listen to the audiocast.

If you experience problems with the primary link, please try this 


Read more
Upcoming Events
Dec 16, 2021
DNB Nordic Healthcare Conference, Oslo

Read more

Annual report 2020

Read more

 

AGM/Generalforsamling

Read more

  • Email Alerts

    Email Alerts

  • Downloads

    Downloads

  • RSS

    RSS

  • Print

    Print

  • Share

    Share

  • English

    English

  • Search

    Search




Select Country Menu

  • Change Country

Quick Links

  • Contact us
  • News
  • Media
  • Vacant jobs
  • Products

ALK Footer Copyright Text

ALK-Abelló A/S ∙ Bøge Allé 6 ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Legal disclaimer © ALK ∙ All rights reserved